Innovent Biologics Inc is committed to transforming the lives of patients through innovative biopharmaceuticals. The company values integrity, excellence, and patient-centricity. Innovent Biologics believes in creating a patient-oriented ecosystem by focusing on extensive research and development efforts, robust clinical trials, and rigorous quality control processes. The company's corporate philosophy centers around leveraging cutting-edge technology, collaborating with global partners, and delivering high-quality and affordable biologics to improve healthcare access worldwide. Innovent Biologics Inc's unwavering dedication to scientific advancement and patient welfare drives its mission to revolutionize the treatment landscape and provide hope for patients in need.

Innovent Biologics Inc is primarily present in China.

Innovent Biologics Inc has achieved significant milestones in its journey. The company has successfully developed and launched several innovative biologics, including multiple oncology and autoimmune disease therapies. Innovent has secured numerous partnerships and collaborations with leading pharmaceutical companies, expanding its global reach and enhancing its product pipeline. Furthermore, the company has received several regulatory approvals, enabling it to bring life-saving treatments to patients around the world. Innovent's commitment to research and development, along with its dedication to improving patient outcomes, has positioned it as a key player in the biopharmaceutical industry.

Innovent Biologics Inc. is a leading biopharmaceutical company specializing in the development and commercialization of innovative biological drugs. Founded in 2011, the company is headquartered in Suzhou, China and has a global presence. Innovent Biologics is committed to addressing unmet medical needs and improving patient outcomes through its extensive pipeline of monoclonal antibodies and other biologics. A key focus of the company is the development of biosimilars, which are highly similar versions of existing biologics with demonstrated equivalence in terms of safety, efficacy, and quality. Innovent Biologics has established strategic partnerships with numerous international pharmaceutical companies, strengthening its position in the global market.

The main competitors of Innovent Biologics Inc in the market include established biopharmaceutical companies such as AstraZeneca, Eli Lilly and Company, Novartis International AG, and Roche Holding AG. These companies also focus on the development of innovative biologics and have a significant presence in the global biopharmaceutical industry. However, Innovent Biologics Inc differentiates itself through its unique product pipeline and strategic collaborations, aiming to offer novel and affordable biologic medicines to patients globally.

Innovent Biologics Inc is primarily active in the biotechnology and pharmaceutical industries.

Innovent Biologics Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of innovative antibody-based drugs. With a focus on the Chinese market, Innovent combines advanced technology platforms, a robust pipeline, and strategic collaborations to address unmet medical needs. The company utilizes its expertise in areas such as cancer, autoimmune, and metabolic diseases to develop novel therapies that offer improved efficacy, safety, and affordability. Innovent's business model revolves around utilizing its research and development capabilities, partnerships, and market insights to bring life-changing biologics to patients in China and beyond.

Innovent Biologics KGV ir -69,34.

Innovent Biologics KUV ir 6,60.

AlleAktien kvalitātes vērtējums Innovent Biologics ir 3/10.

gaidāmā Innovent Biologics apgrozījums ir 8,13 miljardi CNY.

gaidāmā Innovent Biologics peļņa ir -774,49 milj. CNY.

Innovent Biologics Inc is a leading biotechnology company in China specializing in the development and manufacturing of innovative biologic cancer therapies. The company was founded in 2011 and has since experienced significant growth. Innovent Biologics Inc offers a wide range of products and services, including the development of new biologics, production and manufacturing of biologics, as well as the marketing and sales of biologics. Innovent has an extensive pipeline of cancer therapies that are approved or in clinical trials both in China and globally. The flagship product of Innovent is Sintilimab, an innovative cancer immunotherapy. It has approval in China for non-small cell lung cancer (NSCLC) and Hodgkin lymphoma (HL), and was approved in China in November 2018. It is the first product developed and approved by a Chinese biopharma company in China, marking a turning point for innovative drug development in China. Sintilimab has also received limited market approval in other countries such as the USA, Europe, and Japan. Another important product in Innovent's pipeline is IBI308, a CTLA-4 antibody being developed in combination with Sintilimab for the treatment of solid tumors. Other key product candidates from Innovent include IBI303 (a HER2 antibody), IBI305 (a CD47 antibody), IBI202 (an EGFR TKI), and IBI101 (an antibody targeting severe eye diseases such as AMD and DME). Innovent also has its own biologics manufacturing capacity to meet the demand for various cancer therapies at a global level. It has a production facility in Suzhou built according to cGMP guidelines and equipped with state-of-the-art equipment and technology. Through the use of advanced technologies and scientific innovations, Innovent aims to achieve faster market approval for their products and enhance competitiveness in the global market. In addition to the development and manufacturing of biologics, Innovent is also engaged in collaborations and partnerships. It has formed partnerships with some of the world's leading biopharma and pharmaceutical companies to further improve and expand its innovative technologies and products. Overall, the business model of Innovent Biologics Inc has revolutionized the cancer market in China and internationally. With a strong focus on research and development, production and marketing strategies, as well as collaborations and partnerships, the company has made a sustainable impact on global cancer treatment. Innovent will continue to explore and develop innovative therapies to meet the challenges of cancer treatment.

Innovent Biologics izmaksā dividendes 0 CNY, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Innovent Biologics vai uzņēmums nedod dividendes.

Innovent Biologics ISIN ir KYG4818G1010.

Innovent Biologics WKN ir A2N7N8.

Innovent Biologics simbols ir 1801.HK.

Pēdējo 12 mēnešu laikā Innovent Biologics maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Innovent Biologics plāno maksāt dividendes 0 CNY apmērā.

Innovent Biologics pašreizējā dividendu rentabilitāte ir .

Innovent Biologics maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Innovent Biologics pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 CNY. Tas atbilst dividendes ražībai 0 %.

Innovent Biologics tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Innovent Biologics apmērā 0 CNY, kas tika izmaksāta 24.11.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 24.11.2024..

Pēdējās dividendes izmaksa notika 24.11.2024..

Gadā 2023, Innovent Biologics izmaksāja 0 CNY dividendes.

Innovent Biologics dividendes tiek izmaksātas CNY.